Is stem cell therapy for Diabetes (Type 1 & 2) FDA-approved?
Lantidra is FDA-approved for a narrow adult Type 1 diabetes indication; it is donor pancreatic-islet cellular therapy, not a generic stem-cell infusion. This approval does not extend to Type 2 diabetes, MSC products, exosomes or another manufacturer's preparation.
How stem cells are studied for Diabetes (Type 1 & 2)
Type 1 diabetes involves autoimmune loss of insulin-producing beta cells; Type 2 diabetes involves heterogeneous combinations of insulin resistance and beta-cell dysfunction. Research includes stem-cell-derived islets, donor islets, encapsulation, gene editing and immune modulation, but these are distinct technologies with different risks and regulatory status. A generic MSC infusion should not be equated with replacement of functional pancreatic islets.
Am I a candidate? → · Diabetes (Type 1 & 2): full overview → · Diabetes (Type 1 & 2) cost → · Cost →
Evidence checked against ISSCR, FDA and EMA guidance. See our editorial standards. This is information, not medical advice. Educational information, not medical advice; figures indicative.
Sources & further reading
More on this condition
- Diabetes (Type 1 & 2): cell-therapy evidence and registered trials
- How much does stem cell therapy for Diabetes (Type 1 & 2) cost? (2026)
- Diabetes (Type 1 & 2) stem cell therapy — your questions answered (2026)
- Diabetes (Type 1 & 2): cell-therapy evidence by therapy class
- MSC vs HSCT for Diabetes (Type 1 & 2): what the registries show